Media

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

November 6, 2025

RenovoRx today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx’s scientific advisory board (SAB).

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

October 13, 2025

RenovoRx today announced the appointment of renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx’s Scientific Advisory Board (SAB).

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

September 25, 2025

RenovoRx today announced that the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry Study (NCT06805461) has been successfully completed at the University of Vermont Cancer Center.

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6, 2025

RenovoRx today announced strong progress in its commercialization efforts, including its growing customer base and the hiring of experienced medical device sales leader Philip Stocton as Senior Director of Sales…

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025

RenovoRx today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 7, 2025

RenovoRx today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025

RenovoRx today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. Johns Hopkins Medicine…

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

March 28, 2025

RenovoRx announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in…

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

March 26, 2025

RenovoRx is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular…

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

March 19, 2025

RenovoRx today is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

February 26, 2025

RenovoRx today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

February 13, 2025

RenovoRx highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference (“SIO 2025”) in Las Vegas, Nevada. The abstract published promising pre-clinical data from the use of…

* Individual results may vary.

First Patient Treated in RenovoCath Clinical Trial

November 10, 2025

RenovoRx Inc.’s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone with the first patient treatment at the University of Vermont Cancer…

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

September 29, 2025

Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.

From Trials to Hope: A New Approach to Treating Pancreatic Cancer

September 27, 2025

Shaun Bagai, CEO of RenovoRx, joined us to discuss an innovative approach delivering chemo directly to pancreatic tumors. By targeting the cancer more precisely, this treatment may reduce side effects…

RenovoRx Panther Study Progresses with First Clinical Procedure

September 26, 2025

RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont Cancer Center, and two additional sites—Baptist Health Miami Cancer Institute and…

How Skipping The CRO Helped RenovoRx Get Closer To Patients

September 24, 2025

In this Q&A, RenovoRx Chief Clinical Officer Leesa Gentry explains why they decided to forgo a CRO partner, discusses their in-house expertise, and shares how the decision helped them get…

PharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma

August 29, 2025

Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.

RenovoRx Updates Pivotal TIGeR-PaC Trial of Pancreatic Cancer Treatment

August 20, 2025

RenovoRx, Inc. announced an update of its ongoing pivotal phase 3 TIGeR-PaC trial, which is evaluating the company’s first investigational drug-device combination oncology product candidate, which uses RenovoRx’s TAMP transarterial…

RenovoRx Launches Post-Marketing Study to Advance Real-World Use of RenovoCath Device

July 28, 2025

RenovoRx’s PanTheR study evaluates the RenovoCath device’s long-term safety and effectiveness in treating solid tumors through real-world data collection.

Interventional Approaches for Locally Advanced Pancreatic Cancer

November 20, 2024

Ripal Gandhi, MD, FSVM, Miami Cardiac and Vascular Institute, Florida, discusses the new and upcoming approaches for treating locally advanced pancreatic cancer. Dr Gandhi touches on both intra-arterial and transvenous…

Trans-Arterial Micro-Perfusion For Improved Drug Delivery

June 19, 2024

The majority of benign and malignant tumors thrive in a highly vascularized microenvironment. Tumors depend on existing or newly formed blood supply to receive oxygen and nutrients, making tumor vasculature…

Intra-Arterial Approach to Locally Advanced Pancreatic Cancer

August 30, 2023

The use of catheter-based localised delivery of drugs for treatment of cancer patients has proven to be effective and provides the benefit of reduced systemic toxicity. A critical prerequisite for…

Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer

August 15, 2023

At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with…

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.